Latest news & insights
Regulatory Rapporteur
Dr Julie Warner, Director of Regulatory Affairs at Boyds, is also the Associate Editor of TOPRA’s Regulatory Rapporteur journal. In the latest issue, Dr Warner,
FDA approval brings first gene therapy to the United States
The FDA issued a historic action, making the first gene therapy available in the United States, ushering in a new approach to the treatment of
Barriers to orphan drug development
This is the second in a series of articles aiming to highlight the vital role that drug development consultants play in helping small pharma companies
EMA issues guidance document in preparation for Brexit
The European Medicines Agency (EMA) and the European Commission have published guidance to help pharma companies prepare for the UK’s withdrawal from the European Union.
New route to treating Alzheimer’s Dementia
Boyds has been working with Australian-based biotech company, Actinogen Medical, to develop a novel approach to the treatment of Alzheimer’s disease. Rather than following the
Falsified medicines – Anything but “fake news”
Dr Julie Warner, Director of Regulatory Affairs at Boyds, is also the Associate Editor of TOPRA’s Regulatory Rapporteur journal. In April, Dr Warner gave an
Brexit’s impact on the European Medicines Agency and notice to Marketing Authorisation Holders
Following the UK’s decision to withdraw from the European Union, the European Medicines Agency(EMA) has been considering the implications for its location and operations. As
Alan Boyd shares his passion for pharmaceutical medicine in BMJ Confidential
Alan Boyd features in this week’s BMJ Confidential, sharing his passion for pharmaceutical medicine, love of chocolate and what makes him happy. Read the full
